Camlin Fine Sciences Limited (NSE:CAMLINFINE)
India · Delayed Price · Currency is INR | Market Cap | 51.02B |
| Revenue (ttm) | 16.67B |
| Net Income (ttm) | -1.39B |
| Shares Out | n/a |
| EPS (ttm) | -7.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 782,147 |
| Average Volume | 313,644 |
| Open | 280.80 |
| Previous Close | 267.45 |
| Day's Range | 257.00 - 280.80 |
| 52-Week Range | 95.59 - 333.30 |
| Beta | 0.62 |
| RSI | 45.26 |
| Earnings Date | Aug 4, 2025 |
About Intra-Cellular Therapies
Camlin Fine Sciences Limited, together with its subsidiaries, research, develops, manufactures, and markets specialty chemicals, ingredients, and additive blend products in India and internationally. The company offers shelf-life solutions, which include basic ingredients, such as tert-butylhydroquinone (TBHQ), Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), and Ascorbyl Palmitate (ASP); aroma ingredients, including vanillin and ethyl vanillin, natural vanillin, and some of its combinations; performance chemicals that include Hy... [Read more]
Financial Performance
In 2024, Camlin Fine Sciences's revenue was 16.67 billion, an increase of 14.62% compared to the previous year's 14.54 billion. Losses were -1.39 billion, 49.9% more than in 2023.
Financial StatementsNews
Camlin Fine Sciences Q3 FY25 results: Revenue rises 8.7% YoY to Rs 435.5 crore, net loss at Rs 158.2 crore
The company attributed the net loss to several factors, including impairments on overseas subsidiaries, non-cash adjustments, and foreign exchange losses.
Top stocks to buy today: Stock recommendations for February 7, 2025
Stock market recommendations: Bajaj Broking Research recommends buying Camlin Fine Sciences and Equinox India Developments for favorable stock positions. The Nifty is expected to sustain a positive bi...